Subscribe
gil-c-shutterstock-com-4
Gil C / Shutterstock.com
23 March 2016Americas

Merck claims hepatitis C patent win

A US court has upheld the validity of two patents owned by Merck in the pharmaceutical company’s dispute with drug maker Gilead centring on hepatitis C treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Gilead v Merck hepatitis C dispute rocked by new allegation
3 May 2016   A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.
Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Gilead v Merck hepatitis C dispute rocked by new allegation
3 May 2016   A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.
Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.

More on this story

Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Gilead v Merck hepatitis C dispute rocked by new allegation
3 May 2016   A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.
Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits